`
`
`
`
`
`
`Entered: December 20, 2016
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________________
`
`PAR PHARMACEUTICAL, INC., BRECKENRIDGE PHARMACEUTICAL,
`INC., AND ROXANE LABORATORIES, INC.
`Petitioners
`
`v.
`
`NOVARTIS AG
`Patent Owner
`_______________________
`Case IPR2016-000841
`U.S. Patent No. 5,665,772
`_______________________
`
`Before LORA M. GREEN, CHRISTOPHER L. CRUMBLEY, and
`ROBERT A. POLLOCK, Administrative Patent Judges.
`
`
`
`PETITIONERS’ REQUEST FOR ORAL ARGUMENT
`
`
`1 Breckenridge Pharmaceutical, Inc. was joined as a party to this proceeding via a
`Motion for Joinder in IPR2016-01023; Roxane Laboratories, Inc. was joined as a
`party via a Motion for Joinder in IPR2016-01102.
`
`
`
`
`
`Case IPR2016-00084
`U.S. Patent No. 5,665,772
`
`
`Pursuant to 37 C.F.R. § 42.70, the Board’s Scheduling Order dated April 29,
`
`2016 (Paper 9), and the Order Modifying Due Date 7, dated December 2, 2016
`
`(Paper 45), Petitioners Par Pharmaceutical, Inc., Breckenridge Pharmaceutical,
`
`Inc., and Roxane Laboratories, Inc. (collectively, “Petitioners”) respectfully
`
`request oral argument on issues related to the patentability of claims 1-3 and 8-10
`
`of U.S. Patent No. 5,665,772 (“’772 patent”) on the instituted grounds set forth in
`
`the Board’s Decision (Paper 8) and on any issues specified in any motions to
`
`exclude, motions for observation regarding cross-examination of reply witnesses,
`
`or any other pending motions filed by the parties. The Board has previously
`
`scheduled the oral argument for February 2, 2017. (Paper 45.)
`
`Petitioners respectfully request that the Board allow Petitioners (collective-
`
`ly) and Patent Owner 45 minutes each to present their arguments, including any
`
`time reserved for rebuttal arguments.
`
`Lead counsel for petitioner Par Pharmaceutical, Daniel Brown, will argue
`
`for the petitioners, but lead counsel for petitioners Breckenridge and Roxane will
`
`attend to address any issues or questions from the Board specific to their clients.
`
`Petitioners respectfully request that the hearing be held in Room A, in order
`
`to accommodate the three law firms representing the three Petitioners, the law firm
`
`representing Patent Owner, as well as client representatives who may wish to at-
`
`tend. Petitioners request permission to use a computer, projector, and screen to dis-
`
`1
`
`
`
`Case IPR2016-00084
`U.S. Patent No. 5,665,772
`
`play demonstratives and exhibits. Petitioners also request that the attorneys at Peti-
`
`tioners’ counsel table be allowed to use computers.
`
`Respectfully submitted,
`
`/Daniel G. Brown/
`By:
`Daniel G. Brown (Reg. No. 54,005)
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`212-906-1200; 212-751-4864 (Fax)
`
`Counsel for Petitioner
`Par Pharmaceutical, Inc.
`
`/Matthew L. Fedowitz/
`By:
`Matthew L. Fedowitz
`(Reg. No. 61,386)
`Merchant & Gould P.C.
`1900 Duke Street, Ste. 600
`Alexandria, VA 22314
`703-684-2500; 703-684-2501 (Fax)
`
`Counsel for Petitioner
`Breckenridge Pharmaceutical, Inc.
`
`/Keith A. Zullow/
`By:
`Keith A. Zullow (Reg. No. 37,975)
`Goodwin Procter LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018-1405
`212-813-8846; 646-558-4226 (Fax)
`
`Counsel for Petitioner
`Roxane Laboratories, Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: December 20, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2016-00084
`U.S. Patent No. 5,665,772
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 20th day of December,
`
`2016, a true and correct copy of the foregoing PETITIONERS’ REQUEST FOR
`
`ORAL ARGUMENT was served by electronic mail on Patent Owner’s lead and
`
`backup counsel at the following email address:
`
`Nicholas N. Kallas (Reg. No. 31,530)
`Raymond R. Mandra (Reg. No. 34,382)
`Peter J. Waibel (Reg. No. 43,228)
`Christina Schwarz (pro hac vice)
`Charlotte Jacobsen (pro hac vice)
`Susanne L. Flanders (pro hac vice)
`Jared L. Stringham (pro hac vice)
`Fitzpatrick, Cella, Harper & Scinto
`1290 Avenue of the Americas
`New York, NY 10104-3800
`ZortressAfinitorIPR@fchs.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By: /Daniel G. Brown/
`
`Daniel G. Brown (Reg. No. 54,005)
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`212-906-1200; 212-751-4864 (Fax)
`
`Counsel for Petitioner
`Par Pharmaceutical, Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1